Mind Medicine Lists on NASDAQ
MNMD becomes the second major high profile billion dollar market cap psychedelic company to list on the NASDAQ.
MNMD becomes the second major high profile billion dollar market cap psychedelic company to list on the NASDAQ.
Rritual Superfoods (CSE: RSF) hit a new all-time high on Friday of $1.15 per share for a gain of 35.29% in only 12 trading days since Psychstocks announced RSF as its latest brand new mushroom pick on March 30th at $0.85 per share!
It was just announced today that Rite Aid will begin to carry the mushroom products of Rritual Superfoods (CSE: RSF) on a nationwide basis!
The first ever psychstock ETF has just begun trading on the Canadian NEO Exchange called Horizons Psychedelic Stock Index ETF (NEO: PSYK).
Psychstocks believes there is only one publicly traded company that is well-positioned to capitalize on rapidly growing interest in DMT and Ayahuasca: Entheon Biomedical (CSE: ENBI), which also trades on the U.S. OTC under the symbol ENTBF.
Our first three Psychstock suggestions have gained an average at their highs of 392.31%!
BetterLife Pharma (CSE: BETR) has announced this morning that it has applied for patent protection of its new 2-Bromo-LSD formulation TD-0148A and its use in the treatment of Major Depressive Disorder (MDD). BETR is beginning its pre-clinical work on TD-0148A in preparation for a Pre-IND Meeting with the FDA in March, which will allow BETR to file its IND to launch clinical trials of TD-0148A for the treatment of MDD later this year!
On the afternoon of December 18th, Psychstocks announced BetterLife Pharma (CSE: BETR) at $1.17 per share as its #1 favorite Psychstock for 2021. BETR closed today at its high of day of $2.25 per share. BETR has already gained by 92.3% in only seven trading days!
BETR is truly establishing the best possible team to take LSD and other psychedelics from experimental to major therapeutic applications.
Our new #1 favorite Psychstock for 2021 is Betterlife Pharma (CSE: BETR) or BETRF on the U.S. OTCQB. BETR is currently trading for $1.17 per share.
Numinus Wellness (TSXV: NUMI) gained as much as 9.87% today to hit a new all-time high of $2.45 per share for a gain of 807.41% since we profiled it as our #1 favorite Psychstock at $0.27 per share!
Revive Therapeutics (CSE: RVV) gained as much as 76.92% today to hit a new record high of $0.92 per share for a gain of 275.51% since we profiled it as our new #1 favorite Psychstock at $0.245 per share!
Psychstocks founder Gerard Adams considers RVV and NUMI to be the two highest quality small-cap stocks in the psychedelic space and their incredibly strong performance is proving Gerard right!
NUMI is pleased about first-of-its-kind policy amendment that will allow legal access to evidence-based treatments to those in need before formal drug approval.
Numinus Wellness (TSXV: NUMI) had its biggest up day in history on Wednesday gaining by 34.83% to finish at a new all-time high closing price of $1.20 per share.
RVV gained by 29.51% to close at its high of day of $0.395 per share and is now up by 61.22% from our initial profile price.
This is perhaps NUMI’s most significant development in its history.
Psychedelics industry bellwether Compass Pathways (CMPS) gained $6.62 or 16.21% today to finish at a new all-time high closing price of $47.45 per share! We consider Revive Therapeutics (CSE: RVV) to be the #1 highest quality small-cap psychedelic biotech play.
RVV provides important update on its oral thin-film delivery system with psilocybin being developed under a research partnership agreement with Reed Research Group out of the University of Wisconsin-Madison.
Oregon residents voted to pass Measure 109 to legalize psilocybin from mushrooms while Washington DC residents voted to pass Initiative 81 to decriminalize natural plant medicines.